The main trial results
Novo said its blockbuster Wegovy helped children with obesity bring down BMI more than placebo over 68 weeks in a late-stage study. On treatment, the average BMI advantage over placebo was 19.7 percentage points, reflecting a 17.4% drop for kids on Wegovy versus a 2.2% gain on placebo. Counting every child in the trial, including those who stopped taking the drug, the average advantage versus placebo was 16.2 percentage points at week 68.
The study ran for two years. Novo also noted that, at the 68-week mark and assuming children stayed on therapy, over 40% of those on Wegovy no longer met the definition of obesity, a result it first flagged in September.
Who was in the study and safety notes
The trial included 167 kids ages 6 to under 12, and every participant received lifestyle support throughout, including calorie-cutting meal plans and higher activity targets. According to Novo, 85% started the trial with moderate or severe obesity - categories that correspond to BMI thresholds of at least 35 and at least 40, in that order. Close to 50% had at least one obesity-related comorbidity - for example, hypertension, high cholesterol, or sleep apnea.
Novo reported that tolerability and overall safety in this pediatric group looked similar to what it has seen in adult studies. The company also said it found no safety signals tied to growth or the timing of puberty.
New breakthroughs in healthcare remind investors that fresh information can reshape long-term opportunities. We're hosting our first ever investor livestream on 11/17 to show you how to use ChatGPT and Claude to invest like a pro, hosted by Briefs Finance CEO Jaspreet Singh. Save your seat.
Why Novo says this matters and what is still unknown
"This is a very significant disease burden in this very young patient population," said Dr. Andrea Traina, Novo's lead medical director for obesity. The company framed childhood obesity as a chronic illness with cardiovascular, metabolic and psychosocial fallout that often carries into adulthood if not addressed.
Wegovy is already cleared to treat obesity for ages 12 and up, but there are no approved drugs for kids under 12. Novo said the new findings suggest Wegovy could help fill that gap by safely and effectively reducing disease severity in children as young as 6. "We are driving towards control of this chronic disease in that patient population when they are still so young and at such high risk for more advanced and accelerated disease progression because they developed it so early," Traina said.
The company also cautioned that the two-year study does not answer whether earlier treatment changes the long-run course of the disease or how care should evolve as children age. "That is something that is still an evidence gap," Traina said.
The bottom line for investors
The data signal a potential expansion of Wegovy's addressable market into younger ages where no medicines are approved today. If regulators ultimately agree, the results could reinforce Novo's obesity franchise and its growth runway, especially given estimates that roughly 177 million children and teens 5 to 19 could be living with obesity in 2025, rising to about 228 million by 2040.
Savvy investors welcome new tools and insights to refine decisions and gain an edge. On 11/17, our CEO Jaspreet Singh goes live for our first ever investor livestream on how to use ChatGPT and Claude to invest like a pro. Register to join him.
